☰

Alexandros Makriyannis - Publications

Affiliations: 
1974- Medicinal Chemistry University of Connecticut, Storrs, CT, United States 
 2004- Northeastern University, Boston, MA, United States 
Area:
Biochemistry
Website:
https://www.ellines.com/en/famous-greeks/30216-pioneer-in-chemical-biology/
Tree Info Similar researchers PubMed Report error

325 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 AlKhelb D, Burke EL, Zvonok A, Iliopoulos-Tsoutsouvas C, Georgiadis MO, Jiang S, Ho TC, Nikas SP, Makriyannis A, Desai RI. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201. European Journal of Pharmacology. 960: 176168. PMID 38059442 DOI: 10.1016/j.ejphar.2023.176168  0.335
2021 Malamas MS, Lamani M, Farah SI, Mohammad KA, Miyabe CY, Rajarshi G, Wu S, Zvonok N, Chandrashekhar H, Wood J, Makriyannis A. Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors. Chemmedchem. PMID 34486233 DOI: 10.1002/cmdc.202100406  0.754
2021 Ho TC, Tius MA, Nikas SP, Tran NK, Tong F, Zhou H, Zvonok N, Makriyannis A. Oxa-Adamantyl Cannabinoids. Bioorganic & Medicinal Chemistry Letters. 127882. PMID 33636308 DOI: 10.1016/j.bmcl.2021.127882  0.323
2021 Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS, Thermos K. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology. 185: 108450. PMID 33450278 DOI: 10.1016/j.neuropharm.2021.108450  0.769
2020 Wooldridge LM, Ji L, Liu Y, Nikas SP, Makriyannis A, Bergman J, Kangas BD. Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates. The Journal of Pharmacology and Experimental Therapeutics. PMID 32561684 DOI: 10.1124/Jpet.120.265710  0.305
2020 Hua T, Li X, Wu L, Iliopoulos-Tsoutsouvas C, Wang Y, Wu M, Shen L, Johnston CA, Nikas SP, Song F, Song X, Yuan S, Sun Q, Wu Y, Jiang S, ... ... Makriyannis A, et al. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G Complex Structures. Cell. PMID 32004463 DOI: 10.1016/J.Cell.2020.01.008  0.389
2019 Malamas MS, Farah SI, Lamani M, Pelekoudas DN, Perry NT, Rajarshi G, Miyabe CY, Chandrashekhar H, West J, Pavlopoulos S, Makriyannis A. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors. Bioorganic & Medicinal Chemistry. 115195. PMID 31761726 DOI: 10.1016/J.Bmc.2019.115195  0.783
2019 Kangas BD, Zakarian AS, Vemuri K, Alapafuja SO, Jiang S, Nikas SP, Makriyannis A, Bergman J. Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates. The Journal of Pharmacology and Experimental Therapeutics. PMID 31641018 DOI: 10.1124/Jpet.119.261818  0.346
2019 Lamani M, Malamas MS, Farah SI, Shukla VG, Almeida MF, Weerts CM, Anderson J, Wood JT, Farizatto KLG, Bahr BA, Makriyannis A. Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. Bioorganic & Medicinal Chemistry. 115096. PMID 31629610 DOI: 10.1016/J.Bmc.2019.115096  0.798
2019 Alapafuja SO, Nikas SP, Ho TC, Tong F, Benchama O, Makriyannis A. Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor. Molecules (Basel, Switzerland). 24. PMID 31581433 DOI: 10.3390/Molecules24193559  0.442
2019 Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656. PMID 31519354 DOI: 10.1016/J.Ejphar.2019.172656  0.342
2019 Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M. In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. British Journal of Pharmacology. PMID 31412133 DOI: 10.1111/Bph.14829  0.388
2019 Ogden SB, Malamas MS, Makriyannis A, Eckel LA. The novel cannabinoid 1 receptor agonist AM11101 increases food intake in female rats. British Journal of Pharmacology. PMID 31328790 DOI: 10.1111/Bph.14797  0.383
2019 Argueta DA, Perez PA, Makriyannis A, DiPatrizio NV. Cannabinoid CB Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity. Frontiers in Physiology. 10: 704. PMID 31281260 DOI: 10.3389/Fphys.2019.00704  0.334
2019 Shields CM, Zvonok N, Zvonok A, Makriyannis A. Biochemical and Proteomic Characterization of Recombinant Human α/β Hydrolase Domain 6. Scientific Reports. 9: 890. PMID 30696836 DOI: 10.1038/S41598-018-36633-4  0.34
2019 Vadivel SK, Whitten KM, Makriyannis A. Chemoenzymatic Synthesis of 2-Arachidonoylglycerol, An Endogenous Ligand for Cannabinoid Receptors. Tetrahedron Letters. 52: 1149-1150. PMID 21318079 DOI: 10.1016/J.Tetlet.2011.01.047  0.4
2018 Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. Molecular Pharmacology. PMID 30504240 DOI: 10.1124/Mol.118.113233  0.344
2018 Chopda GR, Nikas SP, Sharma R, Kulkarni S, Makriyannis A, Paronis CA. Cannabinoid-induced lower lip retraction in rats. Psychopharmacology. PMID 30460515 DOI: 10.1007/S00213-018-5125-Z  0.301
2018 Alapafuja SO, Malamas MS, Shukla V, Zvonok A, Miller S, Daily L, Rajarshi G, Miyabe CY, Chandrashekhar H, Wood J, Tyukhtenko S, Straiker A, Makriyannis A. Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment. Bioorganic & Medicinal Chemistry. PMID 30446439 DOI: 10.1016/J.Bmc.2018.11.003  0.379
2018 Szymanski D, Papanastasiou M, Pandarinathan L, Zvonok N, Janero DR, Pavlopoulos S, Vouros P, Makriyannis A. Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins. Journal of Medicinal Chemistry. PMID 30444608 DOI: 10.1021/Acs.Jmedchem.8B01302  0.414
2018 Sagheddu C, Scherma M, Congiu M, Fadda P, Carta G, Banni S, Wood JT, Makriyannis A, Malamas MS, Pistis M. Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. Neuropharmacology. 144: 327-336. PMID 30439418 DOI: 10.1016/J.Neuropharm.2018.11.013  0.316
2018 Slivicki RA, Saberi SA, Iyer V, Vemuri K, Makriyannis A, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit. The Journal of Pharmacology and Experimental Therapeutics. PMID 30275151 DOI: 10.1124/Jpet.118.252288  0.321
2018 Iliopoulos-Tsoutsouvas C, Kulkarni RN, Makriyannis A, Nikas SP. Fluorescent probes for G-protein-coupled receptor drug discovery. Expert Opinion On Drug Discovery. 1-15. PMID 30249143 DOI: 10.1080/17460441.2018.1518975  0.351
2018 Liu Y, Ji L, Eno M, Kudalkar S, Li A, Schimpgen M, Benchama O, Morales P, Xu S, Hurst DP, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis D, ... ... Makriyannis A, et al. (R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry. PMID 30196704 DOI: 10.1021/Acs.Jmedchem.8B00611  0.365
2018 Malamas MS, Raghav JG, Ma X, Honrao C, Wood JT, Benchama O, Zhou H, Mallipeddi S, Makriyannis A. Oximes short-acting CB1 receptor agonists. Bioorganic & Medicinal Chemistry. PMID 30122284 DOI: 10.1016/J.Bmc.2018.08.003  0.421
2018 Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology. PMID 30121173 DOI: 10.1016/J.Ejphar.2018.08.016  0.372
2018 He XH, Jordan CJ, Vemuri K, Bi GH, Zhan J, Gardner EL, Makriyannis A, Wang YL, Xi ZX. Cannabinoid CB receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. Acta Pharmacologica Sinica. PMID 29967454 DOI: 10.1038/S41401-018-0059-X  0.332
2018 Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A. Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure. Pharmaceuticals (Basel, Switzerland). 11. PMID 29786643 DOI: 10.3390/Ph11020050  0.398
2018 Mallipeddi S, Zvonok N, Makriyannis A. Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Scientific Reports. 8: 2935. PMID 29440756 DOI: 10.1038/S41598-018-19749-5  0.398
2018 Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J. Long-lasting in vivo effects of the cannabinoid CB1 antagonist AM6538. The Journal of Pharmacology and Experimental Therapeutics. PMID 29311110 DOI: 10.1124/Jpet.117.245647  0.357
2017 Leonard MZ, Alapafuja SO, Ji L, Shukla VG, Liu Y, Nikas SP, Makriyannis A, Bergman J, Kangas BD. Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors. The Journal of Pharmacology and Experimental Therapeutics. PMID 28947487 DOI: 10.1124/Jpet.117.244392  0.388
2017 Karageorgos I, Silin VI, Zvonok N, Marino J, Janero DR, Makriyannis A. The role of human monoacylglycerol lipase (hMAGL) binding pocket in breakup of unsaturated phospholipid membranes. Analytical Biochemistry. PMID 28822686 DOI: 10.1016/J.Ab.2017.08.009  0.302
2017 Farizatto KLG, McEwan SA, Naidoo V, Nikas SP, Shukla VG, Almeida MF, Byrd A, Romine H, Karanian DA, Makriyannis A, Bahr BA. Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon. Journal of Molecular Neuroscience : Mn. PMID 28803438 DOI: 10.1007/S12031-017-0963-4  0.308
2017 Janero DR, Korde A, Makriyannis A. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains. Methods in Enzymology. 593: 217-235. PMID 28750804 DOI: 10.1016/Bs.Mie.2017.06.022  0.421
2017 Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA. CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats. Behavioral Neuroscience. 131: 304-311. PMID 28714716 DOI: 10.1037/Bne0000201  0.321
2017 Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, ... ... Makriyannis A, et al. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. PMID 28678776 DOI: 10.1038/Nature23272  0.412
2017 Ho TC, Shimada N, Tius MA, Nikas SP, Zhang W, Makriyannis A. C1'-Azacycloalkyl Hexahydrocannabinols. The Journal of Organic Chemistry. PMID 28677397 DOI: 10.1021/Acs.Joc.7B00988  0.324
2017 Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Kiran Vemuri V, Makriyannis A, Glass M. Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology. PMID 28516479 DOI: 10.1111/Bph.13866  0.369
2017 Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, Gruden G. Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 28387811 DOI: 10.1093/Ndt/Gfx010  0.313
2017 Mallipeddi S, Kreimer S, Zvonok N, Vemuri VK, Karger BL, Ivanov AR, Makriyannis A. Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis. Journal of Proteome Research. PMID 28374590 DOI: 10.1021/Acs.Jproteome.7B00023  0.427
2017 Zhou H, Peng Y, Halikhedkar A, Fan P, Janero DR, Thakur GA, Mercier RW, Sun X, Ma X, Makriyannis A. Human Cannabinoid Receptor 2 Ligand-interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. Acs Chemical Neuroscience. PMID 28220706 DOI: 10.1021/Acschemneuro.7B00003  0.395
2017 McLaughlin PJ, Jagielo-Miller JE, Plyler ES, Schutte KK, Vemuri VK, Makriyannis A. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor. Psychopharmacology. PMID 28144708 DOI: 10.1007/S00213-017-4548-2  0.361
2016 Mallipeddi S, Janero DR, Zvonok N, Makriyannis A. Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets. Biochemical Pharmacology. PMID 27890725 DOI: 10.1016/J.Bcp.2016.11.014  0.392
2016 Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, Laprairie RB, Stahl EL, Ho JH, Zvonok N, Zhou H, ... ... Makriyannis A, et al. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell. 167: 750-762.e14. PMID 27768894 DOI: 10.1016/J.Cell.2016.10.004  0.392
2016 Kulkarni S, Nikas SP, Sharma R, Jiang S, Paronis CA, Leonard MZ, Zhang B, Honrao C, Mallipeddi S, Raghav JG, Benchama O, Järbe TU, Bergman J, Makriyannis A. Novel C-Ring-Hydroxy-substituted Controlled Deactivation Cannabinergic Analogues. Journal of Medicinal Chemistry. PMID 27367336 DOI: 10.1021/Acs.Jmedchem.6B00717  0.33
2016 Järbe TU, LeMay BJ, Thakur GA, Makriyannis A. A High Efficacy Cannabinergic Ligand (AM4054) used as a Discriminative Stimulus: Generalization to other Adamantyl Analogs and Δ(9)-THC in Rats. Pharmacology, Biochemistry, and Behavior. PMID 27264437 DOI: 10.1016/J.Pbb.2016.06.001  0.413
2016 Gueye AB, Trigo JM, Vemuri KV, Makriyannis A, Le Foll B. Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling. Behavioural Pharmacology. 27: 258-69. PMID 26905189 DOI: 10.1097/Fbp.0000000000000222  0.338
2016 Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J, Goldberg SR, Justinova Z. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26888056 DOI: 10.1038/Npp.2016.27  0.355
2016 Kangas BD, Leonard MZ, Shukla VG, Alapafuja SO, Nikas SP, Makriyannis A, Bergman J. Comparisons of Δ9-tetrahydrocannabinol and Anandamide on a Battery of Cognition-related Behavior in Nonhuman Primates. The Journal of Pharmacology and Experimental Therapeutics. PMID 26826191 DOI: 10.1124/Jpet.115.228189  0.324
2016 Gardner EL, Bi G, Thakur G, Makriyannis A, Seltzman HH, He X, Xi Z. PM288. Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction The International Journal of Neuropsychopharmacology. 19: 3-3. DOI: 10.1093/Ijnp/Pyw041.288  0.391
2015 Guo JJ, Yang DP, Tian X, Kiran Vemuri V, Yin D, Li C, Duclos RI, Shen L, Ma X, Janero DR, Makriyannis A. 17β-estradiol (E2) in membranes: Orientation and dynamic properties. Biochimica Et Biophysica Acta. PMID 26607010 DOI: 10.1016/J.Bbamem.2015.11.015  0.484
2015 Panlilio LV, Thorndike EB, Nikas SP, Alapafuja SO, Bandiera T, Cravatt BF, Makriyannis A, Piomelli D, Goldberg SR, Justinova Z. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Psychopharmacology. PMID 26558620 DOI: 10.1007/S00213-015-4140-6  0.327
2015 Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A, Cascio MG, Pertwee RG, Thakur GA. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). Journal of Medicinal Chemistry. PMID 26529344 DOI: 10.1021/Acs.Jmedchem.5B01303  0.405
2015 Järbe TU, Gifford RS, Zvonok A, Makriyannis A. [INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats. Behavioural Pharmacology. PMID 26397760 DOI: 10.1097/Fbp.0000000000000196  0.417
2015 Janero DR, Yaddanapudi S, Zvonok N, Subramanian KV, Shukla VG, Stahl E, Zhou L, Hurst D, Wager-Miller J, Bohn LM, Reggio PH, Mackie K, Makriyannis A. Molecular-Interaction and Signaling Profiles of AM3677, a Novel Covalent Agonist Selective for the Cannabinoid 1 Receptor. Acs Chemical Neuroscience. PMID 25978068 DOI: 10.1021/Acschemneuro.5B00090  0.738
2015 Shelnut EL, Nikas SP, Finnegan DF, Chiang N, Serhan CN, Makriyannis A. Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Letters. 56: 1411-1415. PMID 25960577 DOI: 10.1016/J.Tetlet.2015.01.164  0.336
2015 Vemuri VK, Makriyannis A. Medicinal chemistry of cannabinoids. Clinical Pharmacology and Therapeutics. 97: 553-8. PMID 25801236 DOI: 10.1002/Cpt.115  0.386
2015 Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, Järbe TU. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Psychopharmacology. 232: 2751-61. PMID 25772338 DOI: 10.1007/S00213-015-3907-0  0.35
2015 Ogawa G, Tius MA, Zhou H, Nikas SP, Halikhedkar A, Mallipeddi S, Makriyannis A. 3'-functionalized adamantyl cannabinoid receptor probes. Journal of Medicinal Chemistry. 58: 3104-16. PMID 25760146 DOI: 10.1021/Jm501960U  0.391
2015 Finnegan DF, Shelnut EL, Nikas SP, Chiang N, Serhan CN, Makriyannis A. Novel tail and head group prostamide probes. Bioorganic & Medicinal Chemistry Letters. 25: 1228-31. PMID 25701254 DOI: 10.1016/J.Bmcl.2015.01.064  0.384
2015 Nikas SP, Sharma R, Paronis CA, Kulkarni S, Thakur GA, Hurst D, Wood JT, Gifford RS, Rajarshi G, Liu Y, Raghav JG, Guo JJ, Järbe TU, Reggio PH, Bergman J, ... Makriyannis A, et al. Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols. Journal of Medicinal Chemistry. 58: 665-81. PMID 25470070 DOI: 10.1021/Jm501165D  0.585
2015 Tyukhtenko S, Chan K, Jiang R, Zhou H, Mercier RW, Yang DP, Makriyannis A, Guo JJ. Hydrogen-bonded His93 as a sensitive probe for identifying inhibitors of the endocannabinoid transport protein FABP7. Chemical Biology & Drug Design. 85: 534-40. PMID 25255720 DOI: 10.1111/Cbdd.12440  0.527
2015 Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biological Psychiatry. 77: 475-87. PMID 24853387 DOI: 10.1016/j.biopsych.2014.04.009  0.3
2015 Silin VI, Karageorgos I, Vanderah DJ, Zvonok N, Marino J, Makriyannis A. The Mechanism of the Disintegration of Phospholipid Membranes with Human Monoacylglycerol Lipase (hMGL) Biophysical Journal. 108: 556a-557a. DOI: 10.1016/J.Bpj.2014.11.3052  0.325
2014 Fichna J, Bawa M, Thakur GA, Tichkule R, Makriyannis A, McCafferty DM, Sharkey KA, Storr M. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. Plos One. 9: e109115. PMID 25275313 DOI: 10.1371/Journal.Pone.0109115  0.374
2014 Ntountaniotis D, Kellici T, Tzakos A, Kolokotroni P, Tselios T, Becker-Baldus J, Glaubitz C, Lin S, Makriyannis A, Mavromoustakos T. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan. Biochimica Et Biophysica Acta. 1838: 2439-50. PMID 24946142 DOI: 10.1016/J.Bbamem.2014.06.003  0.391
2014 Sharma R, Nikas SP, Guo JJ, Mallipeddi S, Wood JT, Makriyannis A. C-ring cannabinoid lactones: a novel cannabinergic chemotype. Acs Medicinal Chemistry Letters. 5: 400-4. PMID 24900848 DOI: 10.1021/Ml4005304  0.588
2014 Janero DR, Makriyannis A. Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems. Acs Chemical Neuroscience. 5: 1097-106. PMID 24866555 DOI: 10.1021/Cn5000875  0.35
2014 Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27. PMID 24742127 DOI: 10.1186/1744-8069-10-27  0.332
2014 Nader J, Rapino C, Gennequin B, Chavant F, Francheteau M, Makriyannis A, Duranti A, Maccarrone M, Solinas M, Thiriet N. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. Neuropharmacology. 87: 214-21. PMID 24709540 DOI: 10.1016/J.Neuropharm.2014.03.014  0.383
2014 Järbe TU, LeMay BJ, Halikhedkar A, Wood J, Vadivel SK, Zvonok A, Makriyannis A. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats. Psychopharmacology. 231: 489-500. PMID 24005529 DOI: 10.1007/S00213-013-3257-8  0.41
2013 Guo JJ, Williams MK, Makriyannis A. Therapeutic Opportunities through the Modulation of Endocannabinoid Transport. Pharmaceutical Regulatory Affairs : Open Access. 3. PMID 25485182 DOI: 10.4172/2167-7689.1000e123  0.378
2013 Zhuang J, Yang DP, Tian X, Nikas SP, Sharma R, Guo JJ, Makriyannis A. Targeting the Endocannabinoid System for Neuroprotection: A (19)F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA. Journal of Pharmaceutics & Pharmacology. 1. PMID 24533425 DOI: 10.13188/2327-204X.1000002  0.535
2013 Sharma R, Nikas SP, Paronis CA, Wood JT, Halikhedkar A, Guo JJ, Thakur GA, Kulkarni S, Benchama O, Raghav JG, Gifford RS, Järbe TU, Bergman J, Makriyannis A. Controlled-deactivation cannabinergic ligands. Journal of Medicinal Chemistry. 56: 10142-57. PMID 24286207 DOI: 10.1021/Jm4016075  0.607
2013 Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, Paronis CA. Diuretic effects of cannabinoid agonists in mice. European Journal of Pharmacology. 721: 64-9. PMID 24099963 DOI: 10.1016/J.Ejphar.2013.09.053  0.37
2013 Miller RL, Thakur GA, Stewart WN, Bow JP, Bajaj S, Makriyannis A, McLaughlin PJ. Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. Experimental and Clinical Psychopharmacology. 21: 416-25. PMID 24099361 DOI: 10.1037/A0033668  0.301
2013 Thakur GA, Bajaj S, Paronis C, Peng Y, Bowman AL, Barak LS, Caron MG, Parrish D, Deschamps JR, Makriyannis A. Novel adamantyl cannabinoids as CB1 receptor probes. Journal of Medicinal Chemistry. 56: 3904-21. PMID 23621789 DOI: 10.1021/Jm4000775  0.434
2013 McLaughlin PJ, Thakur GA, Vemuri VK, McClure ED, Brown CM, Winston KM, Wood JT, Makriyannis A, Salamone JD. Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. Pharmacology, Biochemistry, and Behavior. 109: 16-22. PMID 23603029 DOI: 10.1016/J.Pbb.2013.04.011  0.415
2013 Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, Abood ME. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. The Journal of Pharmacology and Experimental Therapeutics. 345: 189-97. PMID 23426954 DOI: 10.1124/Jpet.112.201046  0.355
2013 Zhuang J, Yang DP, Nikas SP, Zhao J, Guo J, Makriyannis A. The interaction of fatty acid amide hydrolase (FAAH) inhibitors with an anandamide carrier protein using (19)F-NMR. The Aaps Journal. 15: 477-82. PMID 23344792 DOI: 10.1208/S12248-013-9455-9  0.512
2013 Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, Bergman J. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. The Journal of Pharmacology and Experimental Therapeutics. 344: 561-7. PMID 23287700 DOI: 10.1124/Jpet.112.201962  0.413
2013 Desai RI, Thakur GA, Vemuri VK, Bajaj S, Makriyannis A, Bergman J. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs. The Journal of Pharmacology and Experimental Therapeutics. 344: 319-28. PMID 23197773 DOI: 10.1124/Jpet.112.198374  0.372
2013 Bowman AL, Makriyannis A. Highly predictive ligand-based pharmacophore and homology models of ABHD6. Chemical Biology & Drug Design. 81: 382-8. PMID 23110439 DOI: 10.1111/Cbdd.12086  0.309
2013 Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, Bergman J. Diuretic effects of cannabinoids. The Journal of Pharmacology and Experimental Therapeutics. 344: 8-14. PMID 23019138 DOI: 10.1124/Jpet.112.199331  0.408
2013 Wood JT, Smith DM, Janero DR, Zvonok AM, Makriyannis A. Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sciences. 92: 482-91. PMID 22749867 DOI: 10.1016/J.Lfs.2012.06.019  0.389
2012 Lu D, Nikas SP, Han XW, Parrish DA, Makriyannis A. Synthesis and characterization of a compact tricyclic resorcinol from (+)- and (-)-3-pinanol. Tetrahedron Letters. 53: 4636-4638. PMID 24052669 DOI: 10.1016/J.Tetlet.2012.05.165  0.311
2012 Alapafuja SO, Nikas SP, Bharathan IT, Shukla VG, Nasr ML, Bowman AL, Zvonok N, Li J, Shi X, Engen JR, Makriyannis A. Sulfonyl fluoride inhibitors of fatty acid amide hydrolase. Journal of Medicinal Chemistry. 55: 10074-89. PMID 23083016 DOI: 10.1021/Jm301205J  0.344
2012 Paronis CA, Nikas SP, Shukla VG, Makriyannis A. Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behavioural Pharmacology. 23: 802-5. PMID 23075707 DOI: 10.1097/Fbp.0B013E32835A7C4D  0.316
2012 West JM, Zvonok N, Whitten KM, Vadivel SK, Bowman AL, Makriyannis A. Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibition. Plos One. 7: e43877. PMID 22952796 DOI: 10.1371/Journal.Pone.0043877  0.301
2012 Dixon DD, Tius MA, Thakur GA, Zhou H, Bowman AL, Shukla VG, Peng Y, Makriyannis A. C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. Bioorganic & Medicinal Chemistry Letters. 22: 5322-5. PMID 22796181 DOI: 10.1016/J.Bmcl.2012.06.013  0.412
2012 Johnston M, Bhatt SR, Sikka S, Mercier RW, West JM, Makriyannis A, Gatley SJ, Duclos RI. Assay and inhibition of diacylglycerol lipase activity Bioorganic and Medicinal Chemistry Letters. 22: 4585-4592. PMID 22738638 DOI: 10.1016/J.Bmcl.2012.05.101  0.321
2012 Naidoo V, Karanian DA, Vadivel SK, Locklear JR, Wood JT, Nasr M, Quizon PM, Graves EE, Shukla V, Makriyannis A, Bahr BA. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 801-13. PMID 22270809 DOI: 10.1007/S13311-011-0100-Y  0.311
2012 Reichenbach V, Ros J, Fernández-Varo G, Casals G, Melgar-Lesmes P, Campos T, Makriyannis A, Morales-Ruiz M, Jiménez W. Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems. The Journal of Pharmacology and Experimental Therapeutics. 340: 629-37. PMID 22160265 DOI: 10.1124/Jpet.111.188078  0.338
2012 Järbe TU, Tai S, LeMay BJ, Nikas SP, Shukla VG, Zvonok A, Makriyannis A. AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology. 220: 417-26. PMID 21989802 DOI: 10.1007/S00213-011-2491-1  0.38
2012 Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, ... Makriyannis A, et al. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. British Journal of Pharmacology. 165: 1556-71. PMID 21883147 DOI: 10.1111/J.1476-5381.2011.01644.X  0.347
2012 Scherma M, Justinová Z, Zanettini C, Panlilio LV, Mascia P, Fadda P, Fratta W, Makriyannis A, Vadivel SK, Gamaleddin I, Le Foll B, Goldberg SR. The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. British Journal of Pharmacology. 165: 2539-48. PMID 21557729 DOI: 10.1111/J.1476-5381.2011.01467.X  0.326
2011 Teng H, Thakur GA, Makriyannis A. Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands. Bioorganic & Medicinal Chemistry Letters. 21: 5999-6002. PMID 21880487 DOI: 10.1016/J.Bmcl.2011.07.017  0.427
2011 Szymanski DW, Papanastasiou M, Melchior K, Zvonok N, Mercier RW, Janero DR, Thakur GA, Cha S, Wu B, Karger B, Makriyannis A. Mass spectrometry-based proteomics of human cannabinoid receptor 2: Covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation Journal of Proteome Research. 10: 4789-4798. PMID 21861534 DOI: 10.1021/Pr2005583  0.383
2011 Järbe TU, Deng H, Vadivel SK, Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behavioural Pharmacology. 22: 498-507. PMID 21836461 DOI: 10.1097/Fbp.0B013E328349Fbd5  0.608
2011 Seif T, Makriyannis A, Kunos G, Bonci A, Hopf FW. The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience. 193: 21-33. PMID 21821098 DOI: 10.1016/J.Neuroscience.2011.07.055  0.379
2011 Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502. PMID 21382397 DOI: 10.1016/J.Pbb.2011.02.024  0.336
2011 Järbe TU, LeMay BJ, Vemuri VK, Vadivel SK, Zvonok A, Makriyannis A. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology. 216: 355-65. PMID 21369753 DOI: 10.1007/S00213-011-2226-3  0.41
2011 Singh SN, Bakshi K, Mercier RW, Makriyannis A, Pavlopoulos S. Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2. Biochemistry. 50: 2223-34. PMID 21306178 DOI: 10.1021/Bi1018144  0.34
2011 Tiburu EK, Tyukhtenko S, Zhou H, Janero DR, Struppe J, Makriyannis A. Human cannabinoid 1 GPCR C-terminal domain interacts with bilayer phospholipids to modulate the structure of its membrane environment. The Aaps Journal. 13: 92-8. PMID 21234731 DOI: 10.1208/S12248-010-9244-7  0.319
2011 Tian X, Pavlopoulos S, Yang DP, Makriyannis A. The interaction of cannabinoid receptor agonists, CP55940 and WIN55212-2 with membranes using solid state 2H NMR. Biochimica Et Biophysica Acta. 1808: 2095-101. PMID 21129361 DOI: 10.1016/J.Bbamem.2010.11.026  0.305
2011 Naidoo V, Nikas SP, Karanian DA, Hwang J, Zhao J, Wood JT, Alapafuja SO, Vadivel SK, Butler D, Makriyannis A, Bahr BA. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. Journal of Molecular Neuroscience : Mn. 43: 493-502. PMID 21069475 DOI: 10.1007/S12031-010-9472-4  0.309
2011 Jiang S, Alberich-Jorda M, Zagozdzon R, Parmar K, Fu Y, Mauch P, Banu N, Makriyannis A, Tenen DG, Avraham S, Groopman JE, Avraham HK. Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood. 117: 827-38. PMID 21063029 DOI: 10.1182/Blood-2010-01-265082  0.371
2011 Cluny NL, Chambers AP, Vemuri VK, Wood JT, Eller LK, Freni C, Reimer RA, Makriyannis A, Sharkey KA. The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacology, Biochemistry, and Behavior. 97: 537-43. PMID 21056053 DOI: 10.1016/J.Pbb.2010.10.013  0.315
2010 Guo J, Duclos RI, Vemuri VK, Makriyannis A. The Conformations of 17β-Estradiol (E2) and 17α-Estradiol as Determined by Solution NMR. Tetrahedron Letters. 51: 3465-3469. PMID 21442021 DOI: 10.1016/J.Tetlet.2010.04.077  0.464
2010 Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, Osei-Hyiaman D, Liu J, Mukhopadhyay B, Harvey-White J, Tam J, Pacak K, Blankman JL, Cravatt BF, Makriyannis A, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chemistry & Biology. 17: 1256-66. PMID 21095576 DOI: 10.1016/J.Chembiol.2010.08.013  0.383
2010 Mercier RW, Pei Y, Pandarinathan L, Janero DR, Zhang J, Makriyannis A. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation. Chemistry & Biology. 17: 1132-42. PMID 21035736 DOI: 10.1016/J.Chembiol.2010.08.010  0.381
2010 Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG, Papahatjis DP, Bowman AL, Halikhedkar A, Han X, Makriyannis A. Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. Journal of Medicinal Chemistry. 53: 6996-7010. PMID 20925434 DOI: 10.1021/Jm100641G  0.365
2010 Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. British Journal of Pharmacology. 161: 629-42. PMID 20880401 DOI: 10.1111/J.1476-5381.2010.00908.X  0.38
2010 Jiang S, Zagozdzon R, Jorda MA, Parmar K, Fu Y, Williams JS, Wood JA, Makriyannis A, Banu N, Avraham S, Groopman JE, Avraham HK. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. The Journal of Biological Chemistry. 285: 35471-8. PMID 20826813 DOI: 10.1074/Jbc.M110.144758  0.307
2010 Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. British Journal of Pharmacology. 161: 336-49. PMID 20735419 DOI: 10.1111/J.1476-5381.2010.00885.X  0.405
2010 Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, Santerre JL, Makriyannis A, Salamone JD. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacology, Biochemistry, and Behavior. 97: 179-84. PMID 20713079 DOI: 10.1016/J.Pbb.2010.07.021  0.314
2010 Selvakumar J, Makriyannis A, Ramanathan CR. An unusual reactivity of BBr(3): Accessing tetrahydroisoquinoline units from N-phenethylimides. Organic & Biomolecular Chemistry. 8: 4056-8. PMID 20664860 DOI: 10.1039/C0Ob00269K  0.666
2010 McLaughlin PJ, Winston KM, Swezey LA, Vemuri VK, Makriyannis A, Salamone JD. Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists. Pharmacology, Biochemistry, and Behavior. 96: 75-81. PMID 20403373 DOI: 10.1016/J.Pbb.2010.04.009  0.321
2010 Sink KS, Segovia KN, Collins LE, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD. The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacology, Biochemistry, and Behavior. 95: 479-84. PMID 20347865 DOI: 10.1016/J.Pbb.2010.03.011  0.371
2010 Papahatjis DP, Nahmias VR, Nikas SP, Schimpgen M, Makriyannis A. Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids. Chemistry (Weinheim An Der Bergstrasse, Germany). 16: 4091-9. PMID 20187040 DOI: 10.1002/Chem.200902880  0.341
2010 Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, Lutz B, Mackie K, Makriyannis A, Macnaughton WK, Sharkey KA. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 787-96, e223. PMID 20180825 DOI: 10.1111/J.1365-2982.2010.01478.X  0.38
2010 Zvonok N, Xu W, Williams J, Janero DR, Krishnan SC, Makriyannis A. Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor. Journal of Proteome Research. 9: 1746-53. PMID 20131867 DOI: 10.1021/Pr900870P  0.363
2010 Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57. PMID 20127295 DOI: 10.1208/S12248-009-9170-8  0.33
2010 Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 112-22. PMID 20015619 DOI: 10.1016/J.Euroneuro.2009.11.002  0.37
2010 Järbe TU, Li C, Vadivel SK, Makriyannis A. Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology. 208: 87-98. PMID 19902182 DOI: 10.1007/S00213-009-1708-Z  0.344
2010 Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sciences. 86: 615-23. PMID 19527737 DOI: 10.1016/J.Lfs.2009.06.003  0.389
2009 Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opinion On Therapeutic Patents. 19: 1647-73. PMID 19939187 DOI: 10.1517/13543770903436505  0.333
2009 Tyukhtenko S, Tiburu EK, Deshmukh L, Vinogradova O, Janero DR, Makriyannis A. NMR solution structure of human cannabinoid receptor-1 helix 7/8 peptide: candidate electrostatic interactions and microdomain formation. Biochemical and Biophysical Research Communications. 390: 441-6. PMID 19766594 DOI: 10.1016/J.Bbrc.2009.09.053  0.318
2009 Sink KS, Segovia KN, Nunes EJ, Collins LE, Vemuri VK, Thakur G, Makriyannis A, Salamone JD. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology. 206: 223-32. PMID 19588124 DOI: 10.1007/S00213-009-1602-8  0.364
2009 Bowman AL, Makriyannis A. Refined homology model of monoacylglycerol lipase: toward a selective inhibitor. Journal of Computer-Aided Molecular Design. 23: 799-806. PMID 19543978 DOI: 10.1007/S10822-009-9289-9  0.368
2009 Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Diseases. 15: 1678-85. PMID 19408320 DOI: 10.1002/Ibd.20960  0.401
2009 Tiburu EK, Tyukhtenko S, Deshmukh L, Vinogradova O, Janero DR, Makriyannis A. Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. Biochemical and Biophysical Research Communications. 384: 243-8. PMID 19397896 DOI: 10.1016/J.Bbrc.2009.04.099  0.334
2009 Janero DR, Vadivel SK, Makriyannis A. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies International Review of Psychiatry. 21: 122-133. PMID 19367506 DOI: 10.1080/09540260902782778  0.35
2009 Tiburu EK, Bowman AL, Struppe JO, Janero DR, Avraham HK, Makriyannis A. Solid-state NMR and molecular dynamics characterization of cannabinoid receptor-1 (CB1) helix 7 conformational plasticity in model membranes. Biochimica Et Biophysica Acta. 1788: 1159-67. PMID 19366584 DOI: 10.1016/J.Bbamem.2009.02.002  0.343
2009 Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion On Emerging Drugs. 14: 43-65. PMID 19249987 DOI: 10.1517/14728210902736568  0.429
2009 Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends in Pharmacological Sciences. 30: 1-7. PMID 19042036 DOI: 10.1016/J.Tips.2008.10.001  0.403
2009 Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacology, Biochemistry, and Behavior. 91: 303-6. PMID 18703081 DOI: 10.1016/J.Pbb.2008.07.013  0.337
2009 Järbe TU, Li C, Liu Q, Makriyannis A. Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacology. 203: 229-39. PMID 18521574 DOI: 10.1007/S00213-008-1199-3  0.392
2009 Wilkerson J, Dengler E, Thakur G, Wallace J, Zvonok A, Makriyannis A, Ashton J, Milligan E. Administration of AM 1241, a cannabinoid 2 (CB2) receptor selective agonist, to the rodent spinal cord reverses Chronic Constriction Injury (CCI) induced allodynia The Journal of Pain. 10: S22. DOI: 10.1016/J.Jpain.2009.01.095  0.302
2008 Duclos RI, Lu D, Guo J, Makriyannis A. Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands. Tetrahedron Letters. 49: 5587-5589. PMID 23935221 DOI: 10.1016/J.Tetlet.2008.07.029  0.518
2008 Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero DR, Makriyannis A. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chemistry & Biology. 15: 1207-19. PMID 19022181 DOI: 10.1016/J.Chembiol.2008.10.011  0.407
2008 Guo J, Yang DP, Chari R, Tian X, Pavlopoulos S, Lu D, Makriyannis A. Magnetically aligned bicelles to study the orientation of lipophilic ligands in membrane bilayers. Journal of Medicinal Chemistry. 51: 6793-9. PMID 18834109 DOI: 10.1021/Jm800766X  0.636
2008 Lu D, Guo J, Duclos RI, Bowman AL, Makriyannis A. Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. Journal of Medicinal Chemistry. 51: 6393-9. PMID 18826296 DOI: 10.1021/Jm8005299  0.585
2008 Magrioti V, Naxakis G, Hadjipavlou-Litina D, Makriyannis A, Kokotos G. A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity Bioorganic & Medicinal Chemistry Letters. 18: 5424-5427. PMID 18819796 DOI: 10.1016/J.Bmcl.2008.09.039  0.317
2008 Yao F, Li C, Vadivel SK, Bowman AL, Makriyannis A. Development of novel tail-modified anandamide analogs. Bioorganic & Medicinal Chemistry Letters. 18: 5912-5. PMID 18723350 DOI: 10.1016/J.Bmcl.2008.07.110  0.353
2008 Zvonok N, Pandarinathan L, Williams J, Johnston M, Karageorgos I, Janero DR, Krishnan SC, Makriyannis A. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chemistry & Biology. 15: 854-62. PMID 18721756 DOI: 10.1016/J.Chembiol.2008.06.008  0.328
2008 Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91. PMID 18664590 DOI: 10.1124/Jpet.108.141994  0.398
2008 Järbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacology, Biochemistry, and Behavior. 91: 84-90. PMID 18640150 DOI: 10.1016/J.Pbb.2008.06.014  0.335
2008 Hodge J, Bow JP, Plyler KS, Vemuri VK, Wisniecki A, Salamone JD, Makriyannis A, McLaughlin PJ. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behavioural Brain Research. 193: 298-305. PMID 18602425 DOI: 10.1016/J.Bbr.2008.06.010  0.376
2008 Zvonok N, Williams J, Johnston M, Pandarinathan L, Janero DR, Li J, Krishnan SC, Makriyannis A. Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. Journal of Proteome Research. 7: 2158-64. PMID 18452279 DOI: 10.1021/Pr700839Z  0.327
2008 Järbe TU, Li C, Vadivel SK, Makriyannis A. Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology. 198: 467-78. PMID 18264696 DOI: 10.1007/S00213-008-1076-0  0.385
2008 Kapur A, Samaniego P, Thakur GA, Makriyannis A, Abood ME. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. The Journal of Pharmacology and Experimental Therapeutics. 325: 341-8. PMID 18174385 DOI: 10.1124/Jpet.107.133256  0.381
2008 Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD. Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology. 196: 565-74. PMID 18004546 DOI: 10.1007/S00213-007-0988-4  0.316
2008 Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology. 54: 129-40. PMID 17904589 DOI: 10.1016/J.Neuropharm.2007.08.011  0.374
2007 Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiology & Behavior. 93: 671-86. PMID 18155257 DOI: 10.1016/J.Physbeh.2007.11.012  0.354
2007 Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Thakur GA, Malan TP, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papahatjis DP, Makriyannis A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. Journal of Medicinal Chemistry. 50: 6493-500. PMID 18038967 DOI: 10.1021/Jm070441U  0.437
2007 Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, Sharkey KA. A neutral CB1 receptor antagonist reduces weight gain in rat. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 293: R2185-93. PMID 17959701 DOI: 10.1152/Ajpregu.00663.2007  0.405
2007 Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Current Psychiatry Reports. 9: 365-373. PMID 17915075 DOI: 10.1007/S11920-007-0047-1  0.308
2007 Järbe TU, DiPatrizio NV, Li C, Makriyannis A. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats. Behavioural Pharmacology. 18: 673-80. PMID 17912052 DOI: 10.1097/Fbp.0B013E3282F00Bbf  0.393
2007 Vadivel SK, Vardarajan S, Duclos RI, Wood JT, Guo J, Makriyannis A. Conformationally constrained analogues of 2-arachidonoylglycerol Bioorganic and Medicinal Chemistry Letters. 17: 5959-5963. PMID 17826996 DOI: 10.1016/J.Bmcl.2007.07.064  0.566
2007 Papahatjis DP, Nahmias VR, Nikas SP, Andreou T, Alapafuja SO, Tsotinis A, Guo J, Fan P, Makriyannis A. C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. Journal of Medicinal Chemistry. 50: 4048-60. PMID 17672444 DOI: 10.1021/Jm070121A  0.527
2007 Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77. PMID 17572696 DOI: 10.1038/Sj.Bjp.0707333  0.391
2007 Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiology & Behavior. 91: 383-8. PMID 17521686 DOI: 10.1016/J.Physbeh.2007.04.013  0.323
2007 Zvonok N, Yaddanapudi S, Williams J, Dai S, Dong K, Rejtar T, Karger BL, Makriyannis A. Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor. Journal of Proteome Research. 6: 2068-79. PMID 17472360 DOI: 10.1021/Pr060671H  0.725
2007 Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, Abood ME. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Molecular Pharmacology. 71: 1512-24. PMID 17384224 DOI: 10.1124/Mol.107.034645  0.382
2007 Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, Goldberg SR. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. The Journal of Pharmacology and Experimental Therapeutics. 321: 370-80. PMID 17210800 DOI: 10.1124/Jpet.106.114124  0.399
2007 Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. British Journal of Pharmacology. 150: 153-63. PMID 17160008 DOI: 10.1038/Sj.Bjp.0706984  0.373
2007 Yaddanapudi S, Zvonok N, Williams J, Thakur G, Vouros P, Makriyannis A. A Ligand Based Structural Biology Approach for the Characterization of the Cannabinoid Receptor Binding Domains The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A614-A  0.698
2007 Hohmann A, Rahn E, Maxwell K, Zvonok A, Makriyannis A. 276 SELECTIVE ACTIVATION OF CANNABINOID CB2 RECEPTORS SUPPRESSES CHEMOTHERAPEUTIC NEUROPATHY EVOKED BY PACLITAXEL AND VINCRISTINE ADMINISTRATION European Journal of Pain. 11: S122-S122. DOI: 10.1016/J.Ejpain.2007.03.291  0.401
2006 Järbe TU, Ross T, DiPatrizio NV, Pandarinathan L, Makriyannis A. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacology, Biochemistry, and Behavior. 85: 243-52. PMID 16996123 DOI: 10.1016/J.Pbb.2006.08.006  0.326
2006 Järbe TU, Lamb RJ, Liu Q, Makriyannis A. Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology. 188: 315-23. PMID 16953384 DOI: 10.1007/S00213-006-0517-X  0.345
2006 Koufaki M, Kiziridi C, Papazafiri P, Vassilopoulos A, Varró A, Nagy Z, Farkas A, Makriyannis A. Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. Bioorganic & Medicinal Chemistry. 14: 6666-78. PMID 16782345 DOI: 10.1016/J.Bmc.2006.05.065  0.303
2006 Dhawan J, Deng H, Gatley SJ, Makriyannis A, Akinfeleye T, Bruneus M, Dimaio AA, Gifford AN. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse (New York, N.Y.). 60: 93-101. PMID 16715483 DOI: 10.1002/Syn.20277  0.653
2006 Pavlopoulos S, Thakur GA, Nikas SP, Makriyannis A. Cannabinoid receptors as therapeutic targets. Current Pharmaceutical Design. 12: 1751-69. PMID 16712486 DOI: 10.2174/138161206776873743  0.425
2006 McLaughlin PJ, Qian L, Wood JT, Wisniecki A, Winston KM, Swezey LA, Ishiwari K, Betz AJ, Pandarinathan L, Xu W, Makriyannis A, Salamone JD. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacology, Biochemistry, and Behavior. 83: 396-402. PMID 16616951 DOI: 10.1016/J.Pbb.2006.02.022  0.369
2006 Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP. CB2 cannabinoid receptor mediation of antinociception. Pain. 122: 36-42. PMID 16563625 DOI: 10.1016/J.Pain.2005.12.018  0.416
2006 Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opinion On Investigational Drugs. 15: 351-65. PMID 16548785 DOI: 10.1517/13543784.15.4.351  0.347
2006 Chen JZ, Han XW, Liu Q, Makriyannis A, Wang J, Xie XQ. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. Journal of Medicinal Chemistry. 49: 625-36. PMID 16420048 DOI: 10.1021/Jm050655G  0.421
2006 Järbe TU, Liu Q, Makriyannis A. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology. 184: 36-45. PMID 16307294 DOI: 10.1007/S00213-005-0225-Y  0.328
2005 Thakur GA, Nikas SP, Li C, Makriyannis A. Structural requirements for cannabinoid receptor probes Handbook of Experimental Pharmacology. 168: 209-246. PMID 16596776 DOI: 10.1007/3-540-26573-2_7  0.426
2005 Thakur GA, Duclos RI, Makriyannis A. Natural cannabinoids: Templates for drug discovery Life Sciences. 78: 454-466. PMID 16242157 DOI: 10.1016/J.Lfs.2005.09.014  0.353
2005 Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (New York, N.Y.). 310: 329-32. PMID 16224028 DOI: 10.1126/Science.1115740  0.393
2005 Li C, Xu W, Vadivel SK, Fan P, Makriyannis A. High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. Journal of Medicinal Chemistry. 48: 6423-9. PMID 16190768 DOI: 10.1021/Jm050272I  0.425
2005 Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, Deschamps JR, Flippen-Anderson JL, Gatley SJ, Makriyannis A. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. Journal of Medicinal Chemistry. 48: 6386-92. PMID 16190764 DOI: 10.1021/Jm050135L  0.633
2005 Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, Abood ME, Reggio PH, Fournier DJ, Makriyannis A. (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Molecular Pharmacology. 68: 1623-35. PMID 16157695 DOI: 10.1124/Mol.105.014407  0.412
2005 Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Medica. 71: 701-5. PMID 16142631 DOI: 10.1055/S-2005-871290  0.434
2005 Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 7813-20. PMID 16120783 DOI: 10.1523/Jneurosci.2347-05.2005  0.376
2005 Makriyannis A, Tian X, Guo J. How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins & Other Lipid Mediators. 77: 210-8. PMID 16099405 DOI: 10.1016/j.prostaglandins.2004.01.010  0.472
2005 Xu W, Filppula SA, Mercier R, Yaddanapudi S, Pavlopoulos S, Cai J, Pierce WM, Makriyannis A. Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. The Journal of Peptide Research : Official Journal of the American Peptide Society. 66: 138-50. PMID 16083441 DOI: 10.1111/J.1399-3011.2005.00283.X  0.721
2005 Souli C, Avlonitis N, Calogeropoulou T, Tsotinis A, Maksay G, Bíró T, Politi A, Mavromoustakos T, Makriyannis A, Reis H, Papadopoulos M. Novel 17beta-substituted conformationally constrained neurosteroids that modulate GABA A receptors. Journal of Medicinal Chemistry. 48: 5203-14. PMID 16078839 DOI: 10.1021/Jm050271Q  0.387
2005 Thakur GA, Nikas SP, Makriyannis A. CB1 cannabinoid receptor ligands Mini-Reviews in Medicinal Chemistry. 5: 631-640. PMID 16026309 DOI: 10.2174/1389557054368772  0.403
2005 Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, Hurst DP, Reggio PH, Deschamps JR, Parrish DA, George C, Järbe TU, Lamb RJ, Makriyannis A. Adamantyl cannabinoids: a novel class of cannabinergic ligands. Journal of Medicinal Chemistry. 48: 4576-85. PMID 15999995 DOI: 10.1021/Jm058175C  0.419
2005 Tian X, Guo J, Yao F, Yang DP, Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. The Journal of Biological Chemistry. 280: 29788-95. PMID 15964843 DOI: 10.1074/Jbc.M502925200  0.543
2005 Makriyannis A, Guo J, Tian X. Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. Life Sciences. 77: 1605-11. PMID 15964025 DOI: 10.1016/J.Lfs.2005.05.008  0.492
2005 McLaughlin PJ, Lu D, Winston KM, Thakur G, Swezey LA, Makriyannis A, Salamone JD. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology, Biochemistry, and Behavior. 81: 78-88. PMID 15894067 DOI: 10.1016/J.Pbb.2005.02.005  0.379
2005 Li Z, Gifford A, Liu Q, Thotapally R, Ding YS, Makriyannis A, Gatley SJ. Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. Nuclear Medicine and Biology. 32: 361-6. PMID 15878505 DOI: 10.1016/J.Nucmedbio.2005.02.007  0.394
2005 Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 2046-57. PMID 15870833 DOI: 10.1038/Sj.Npp.1300754  0.386
2005 Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proceedings of the National Academy of Sciences of the United States of America. 102: 3093-8. PMID 15705714 DOI: 10.1073/Pnas.0409888102  0.385
2005 Karanian DA, Brown QB, Makriyannis A, Bahr BA. Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. European Journal of Pharmacology. 508: 47-56. PMID 15680253 DOI: 10.1016/J.Ejphar.2004.12.009  0.306
2005 Choi G, Guo J, Makriyannis A. The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. Biochimica Et Biophysica Acta. 1668: 1-9. PMID 15670725 DOI: 10.1016/J.Bbamem.2004.10.011  0.567
2004 Nikas SP, Grzybowska J, Papahatjis DP, Charalambous A, Banijamali AR, Chari R, Fan P, Kourouli T, Lin S, Nitowski AJ, Marciniak G, Guo Y, Li X, Wang CL, Makriyannis A. The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. The Aaps Journal. 6: e30. PMID 15760095 DOI: 10.1208/Aapsj060430  0.622
2004 Filppula S, Yaddanapudi S, Mercier R, Xu W, Pavlopoulos S, Makriyannis A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. The Journal of Peptide Research : Official Journal of the American Peptide Society. 64: 225-36. PMID 15613086 DOI: 10.1111/J.1399-3011.2004.00188.X  0.724
2004 Järbe TU, DiPatrizio NV, Lu D, Makriyannis A. (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behavioural Pharmacology. 15: 517-21. PMID 15472574 DOI: 10.1097/00008877-200411000-00008  0.438
2004 Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. Journal of Neurophysiology. 92: 3562-74. PMID 15317842 DOI: 10.1152/Jn.00886.2003  0.315
2004 Czoty PW, Ramanathan CR, Mutschler NH, Makriyannis A, Bergman J. Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 311: 720-7. PMID 15240827 DOI: 10.1124/Jpet.104.071035  0.692
2004 Järbe TU, Harris MY, Li C, Liu Q, Makriyannis A. Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology. 177: 35-45. PMID 15167981 DOI: 10.1007/S00213-004-1916-5  0.384
2004 Luk T, Jin W, Zvonok A, Lu D, Lin XZ, Chavkin C, Makriyannis A, Mackie K. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. British Journal of Pharmacology. 142: 495-500. PMID 15148260 DOI: 10.1038/Sj.Bjp.0705792  0.39
2004 Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America. 101: 8756-61. PMID 15138300 DOI: 10.1073/Pnas.0400997101  0.716
2004 Arizzi MN, Cervone KM, Aberman JE, Betz A, Liu Q, Lin S, Makriyannis A, Salamone JD. Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Life Sciences. 74: 1001-11. PMID 14672756 DOI: 10.1016/J.Lfs.2003.07.024  0.345
2004 Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. The Journal of Pharmacology and Experimental Therapeutics. 308: 446-53. PMID 14610224 DOI: 10.1124/Jpet.103.060079  0.391
2003 McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishiwari K, Makriyannis A, Salamone JD. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioural Pharmacology. 14: 583-8. PMID 14665975 DOI: 10.1097/00008877-200312000-00002  0.342
2003 Guo J, Pavlopoulos S, Tian X, Lu D, Nikas SP, Yang DP, Makriyannis A. Conformational study of lipophilic ligands in phospholipid model membrane systems by solution NMR. Journal of Medicinal Chemistry. 46: 4838-46. PMID 14584935 DOI: 10.1021/Jm020385R  0.526
2003 Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology. 99: 955-60. PMID 14508331 DOI: 10.1097/00000542-200310000-00031  0.423
2003 Järbe TU, DiPatrizio NV, Li C, Makriyannis A. The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacology, Biochemistry, and Behavior. 75: 809-21. PMID 12957223 DOI: 10.1016/S0091-3057(03)00168-0  0.354
2003 Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proceedings of the National Academy of Sciences of the United States of America. 100: 10529-33. PMID 12917492 DOI: 10.1073/Pnas.1834309100  0.635
2003 Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. Journal of Medicinal Chemistry. 46: 3221-9. PMID 12852753 DOI: 10.1021/Jm020558C  0.599
2003 Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 119: 747-57. PMID 12809695 DOI: 10.1016/S0306-4522(03)00126-X  0.336
2003 Järbe TU, Lamb RJ, Liu Q, Makriyannis A. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. European Journal of Pharmacology. 466: 121-7. PMID 12679148 DOI: 10.1016/S0014-2999(03)01491-2  0.355
2003 Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry. 84: 1097-109. PMID 12603833 DOI: 10.1046/J.1471-4159.2003.01595.X  0.386
2003 Malan TP, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Current Opinion in Pharmacology. 3: 62-7. PMID 12550743 DOI: 10.1016/S1471-4892(02)00004-8  0.384
2003 Chu C, Ramamurthy A, Makriyannis A, Tius MA. Synthesis of covalent probes for the radiolabeling of the cannabinoid receptor. The Journal of Organic Chemistry. 68: 55-61. PMID 12515461 DOI: 10.1021/Jo0264978  0.418
2003 Gifford AN, Makriyannis A, Volkow ND, Gatley SJ. In vivo imaging of the brain cannabinoid receptor. Chemistry and Physics of Lipids. 121: 65-72. PMID 12505691 DOI: 10.1016/S0009-3084(02)00148-2  0.365
2003 Papahatjis DP, Nikas SP, Andreou T, Makriyannis A. Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. Bioorganic & Medicinal Chemistry Letters. 12: 3583-6. PMID 12443781 DOI: 10.1016/S0960-894X(02)00785-0  0.362
2003 Yao FM, Palmer SL, Khanolkar AD, Tian X, Guo J, Makriyannis A. Synthesis of 15N-, 13C-, and 2H-labeled methanandamide analogs Journal of Labelled Compounds and Radiopharmaceuticals. 46: 115-129. DOI: 10.1002/Jlcr.650  0.526
2002 Thakur GA, Palmer SL, Harrington PE, Stergiades IA, Tius MA, Makriyannis A. Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. Journal of Biochemical and Biophysical Methods. 54: 415-22. PMID 12543516 DOI: 10.1016/S0165-022X(02)00144-6  0.431
2002 Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F. Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chemistry and Physics of Lipids. 121: 191-200. PMID 12505700 DOI: 10.1016/S0009-3084(02)00155-X  0.402
2002 Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chemistry and Physics of Lipids. 121: 3-19. PMID 12505686 DOI: 10.1016/S0009-3084(02)00143-3  0.313
2002 Picone RP, Fournier DJ, Makriyannis A. Ligand based structural studies of the CB1 cannabinoid receptor. The Journal of Peptide Research : Official Journal of the American Peptide Society. 60: 348-56. PMID 12464113 DOI: 10.1034/J.1399-3011.2002.21069.X  0.407
2002 Schuel H, Burkman LJ, Lippes J, Crickard K, Mahony MC, Giuffrida A, Picone RP, Makriyannis A. Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Molecular Reproduction and Development. 63: 376-87. PMID 12237954 DOI: 10.1002/Mrd.90021  0.311
2002 Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacology & Therapeutics. 95: 103-17. PMID 12182958 DOI: 10.1016/S0163-7258(02)00250-4  0.769
2002 Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett SM. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochemical and Biophysical Research Communications. 290: 91-6. PMID 11779138 DOI: 10.1006/Bbrc.2001.6179  0.309
2002 Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. Aaps Pharmsci. 1: E4. PMID 11741201 DOI: 10.1208/Ps010204  0.422
2002 Xie X, Yang H, Choi G, Lin S, Makriyannis A. Synthesis of15N and13C selectively labeled anandamide Journal of Labelled Compounds and Radiopharmaceuticals. 45: 775-784. DOI: 10.1002/Jlcr.601  0.399
2001 Malan TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93: 239-45. PMID 11514083 DOI: 10.1016/S0304-3959(01)00321-9  0.637
2001 Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine. 7: 827-32. PMID 11433348 DOI: 10.1038/89953  0.329
2001 Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorganic & Medicinal Chemistry. 9: 1673-84. PMID 11425567 DOI: 10.1016/S0968-0896(01)00088-8  0.765
2001 Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan TP. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology. 94: 882-7. PMID 11388542 DOI: 10.1097/00000542-200105000-00029  0.381
2001 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model The Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 300-302. PMID 11156943 DOI: 10.1096/Fj.00-0399Fje  0.321
2000 Khanolkar AD, Palmer SL, Makriyannis A. Molecular probes for the cannabinoid receptors. Chemistry and Physics of Lipids. 108: 37-52. PMID 11106781 DOI: 10.1016/S0009-3084(00)00186-9  0.431
2000 Palmer SL, Khanolkar AD, Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Current Pharmaceutical Design. 6: 1381-97. PMID 10903399 DOI: 10.2174/1381612003399419  0.434
2000 Lamb RJ, Järbe TU, Makriyannis A, Lin S, Goutopoulos A. Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing. European Journal of Pharmacology. 398: 251-8. PMID 10854837 DOI: 10.1016/S0014-2999(00)00318-6  0.711
2000 Howlett AC, Wilken GH, Pigg JJ, Houston DB, Lan R, Liu Q, Makriyannis A. Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction. Journal of Neurochemistry. 74: 2174-81. PMID 10800963 DOI: 10.1046/J.1471-4159.2000.0742174.X  0.43
2000 Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells Biochemical Journal. 346: 835-840. PMID 10698714 DOI: 10.1042/Bj3460835  0.356
1999 Gifford AN, Bruneus M, Lin S, Goutopoulos A, Makriyannis A, Volkow ND, Gatley SJ. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). European Journal of Pharmacology. 383: 9-14. PMID 10556675 DOI: 10.1016/S0014-2999(99)00609-3  0.737
1999 Xie XQ, Han XW, Chen JZ, Eissenstat M, Makriyannis A. High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2. Journal of Medicinal Chemistry. 42: 4021-7. PMID 10514272 DOI: 10.1021/Jm980592K  0.361
1999 Khanolkar AD, Lu D, Fan P, Tian X, Makriyannis A. Novel conformationally restricted tetracyclic analogs of δ8- tetrahydrocannabinol Bioorganic and Medicinal Chemistry Letters. 9: 2119-2124. PMID 10465529 DOI: 10.1016/S0960-894X(99)00355-8  0.37
1999 Khanolkar AD, Makriyannis A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand Life Sciences. 65: 607-616. PMID 10462061 DOI: 10.1016/S0024-3205(99)00283-0  0.429
1999 González S, Romero J, de Miguel R, Lastres-Becker I, Villanua MA, Makriyannis A, Ramos JA, Fernández-Ruiz JJ. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sciences. 65: 327-36. PMID 10447218 DOI: 10.1016/S0024-3205(99)00251-9  0.317
1999 Romero J, Berrendero F, García-Gil L, Lin SY, Makriyannis A, Ramos JA, Fernández-Ruiz JJ. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Neurochemistry International. 34: 473-82. PMID 10402222 DOI: 10.1016/S0197-0186(99)00020-0  0.377
1999 Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America. 96: 5802-7. PMID 10318965 DOI: 10.1073/pnas.96.10.5802  0.704
1999 Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. Journal of Medicinal Chemistry. 42: 1682. PMID 10231226 DOI: 10.1021/jm990139o  0.678
1999 Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. British Journal of Pharmacology. 126: 665-72. PMID 10188977 DOI: 10.1038/Sj.Bjp.0702351  0.375
1999 Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. Journal of Medicinal Chemistry. 42: 896-902. PMID 10072686 DOI: 10.1021/Jm980461J  0.766
1999 Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. Journal of Medicinal Chemistry. 42: 769-76. PMID 10052983 DOI: 10.1021/Jm980363Y  0.429
1998 Järbe TU, Sheppard R, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A. Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behavioural Pharmacology. 9: 169-74. PMID 10065936  0.703
1998 Järbe TU, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A. Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology. 140: 519-22. PMID 9888629 DOI: 10.1007/S002130050797  0.722
1998 Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. Journal of Medicinal Chemistry. 41: 5353-61. PMID 9876105 DOI: 10.1021/Jm970257G  0.774
1998 de Miguel R, Romero J, Muñoz RM, García-Gil L, González S, Villanua MA, Makriyannis A, Ramos JA, Fernández-Ruiz JJ. Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochemical Pharmacology. 56: 1331-8. PMID 9825732 DOI: 10.1016/S0006-2952(98)00185-3  0.385
1998 Berglund BA, Boring DL, Wilken GH, Makriyannis A, Howlett AC, Lin S. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 59: 111-8. PMID 9774174 DOI: 10.1016/S0952-3278(98)90089-8  0.431
1998 Drake DJ, Jensen RS, Busch-Petersen J, Kawakami JK, Concepcion Fernandez-Garcia M, Fan P, Makriyannis A, Tius MA. Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues. Journal of Medicinal Chemistry. 41: 3596-608. PMID 9733485 DOI: 10.1021/Jm960677Q  0.31
1998 Qin C, Lin S, Lang W, Goutopoulos A, Pavlopoulos S, Mauri F, Makriyannis A. Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography. Analytical Biochemistry. 261: 8-15. PMID 9683506 DOI: 10.1006/Abio.1998.2713  0.725
1998 Carriero D, Aberman J, Lin SY, Hill A, Makriyannis A, Salamone JD. A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology. 137: 147-56. PMID 9630001 DOI: 10.1007/S002130050604  0.359
1998 Paria BC, Ma W, Andrenyak DM, Schmid PC, Schmid HH, Moody DE, Deng H, Makriyannis A, Dey SK. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biology of Reproduction. 58: 1490-5. PMID 9623610  0.533
1998 Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols. Journal of Medicinal Chemistry. 41: 1195-200. PMID 9544219 DOI: 10.1021/Jm970277I  0.761
1998 Landsman RS, Makriyannis A, Deng H, Consroe P, Roeske WR, Yamamura HI. AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sciences. 62: PL109-13. PMID 9496703 DOI: 10.1016/S0024-3205(97)01187-9  0.616
1998 Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neuroscience Letters. 238: 84-6. PMID 9464661 DOI: 10.1016/S0304-3940(97)00851-3  0.361
1998 Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A. Imaging the brain marijuana receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo Journal of Neurochemistry. 70: 417-423. PMID 9422389 DOI: 10.1046/J.1471-4159.1998.70010417.X  0.417
1997 Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. European Journal of Pharmacology. 337: R1-2. PMID 9389389 DOI: 10.1016/S0014-2999(97)01297-1  0.327
1997 Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sciences. 61: PL 191-7. PMID 9335234 DOI: 10.1016/S0024-3205(97)00690-5  0.375
1997 Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makriyannis A, Consroe P, Roeske WR, Yamamura HI. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sciences. 61: PL115-8. PMID 9284087 DOI: 10.1016/S0024-3205(97)00596-1  0.379
1997 Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (New York, N.Y.). 277: 1094-7. PMID 9262477 DOI: 10.1126/Science.277.5329.1094  0.394
1997 Fernández-Ruiz JJ, Muñoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochemical Pharmacology. 53: 1919-27. PMID 9256167 DOI: 10.1016/S0006-2952(97)00168-8  0.383
1997 Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. European Journal of Pharmacology. 321: R1-3. PMID 9083796 DOI: 10.1016/S0014-2999(97)00047-2  0.386
1997 Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, Omeir RL, Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochemical and Biophysical Research Communications. 231: 217-21. PMID 9070252 DOI: 10.1006/Bbrc.1997.6072  0.39
1997 Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. European Journal of Pharmacology. 307: 331-8. PMID 8836622 DOI: 10.1016/0014-2999(96)00279-8  0.349
1996 Mavromoustakos T, Theodoropoulou E, Yang DP, Lin SY, Koufaki M, Makriyannis A. The conformational properties of the antineoplastic ether lipid 1-thiohexadecyl-2-O-methyl-S-glycero-3-phosphocholine Chemistry and Physics of Lipids. 84: 21-34. PMID 8952050 DOI: 10.1016/S0009-3084(96)02615-1  0.318
1996 Khanolkar AD, Abadji V, Lin S, Hill WAG, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand Journal of Medicinal Chemistry. 39: 4515-4519. PMID 8893848 DOI: 10.1021/Jm960152Y  0.434
1996 Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA, Makriyannis A. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. Journal of Medicinal Chemistry. 39: 3790-6. PMID 8809166 DOI: 10.1021/Jm950934B  0.377
1996 Tsotinis A, Calogeropoulou T, Koufaki M, Souli C, Balzarini J, Clercq ED, Makriyannis A. Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine. Journal of Medicinal Chemistry. 39: 3418-3422. PMID 8765527 DOI: 10.1021/Jm950777G  0.304
1996 Koufaki M, Polychroniou V, Calogeropoulou T, Tsotinis A, Drees M, Fiebig HH, LeClerc S, Hendriks HR, Makriyannis A. Alkyl and alkoxyethyl antineoplastic phospholipids. Journal of Medicinal Chemistry. 39: 2609-2614. PMID 8691459 DOI: 10.1021/Jm9509152  0.304
1996 Xie XQ, Melvin LS, Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940 Journal of Biological Chemistry. 271: 10640-10647. PMID 8631869 DOI: 10.1074/Jbc.271.18.10640  0.379
1996 Romero J, García-Palomero E, Lin SY, Ramos JA, Makriyannis A, Fernández-Ruiz JJ. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sciences. 58: 1249-57. PMID 8614278 DOI: 10.1016/0024-3205(96)00086-0  0.337
1996 Tius MA, Kawakami JK, Hill WAG, Makriyannis A. Selectivity in aromatic fluorination. Introduction of fluorine probes into nabilone Chemical Communications. 2085-2086. DOI: 10.1039/Cc9960002085  0.379
1996 D'Ambra TE, Eissenstat MA, Abt J, Ackerman JH, Bacon ER, Bell MR, Carabateas PM, Josef KA, Kumar V, Weaver JD, Arnold R, Casiano FM, Chippari SM, Haycock DA, Kuster JE, ... ... Makriyannis A, et al. C-attached aminoalkylindoles: Potent cannabinoid mimetics Bioorganic and Medicinal Chemistry Letters. 6: 17-22. DOI: 10.1016/0960-894X(95)00560-G  0.312
1996 Cody V, Li N, Khanolkar AD, Makriyannis A, Froimowitz M. Crystal structure of the meta hydroxyl phenyl analog of α(+)-prodine Journal of Chemical Crystallography. 26: 601-605. DOI: 10.1007/Bf01668620  0.301
1996 Lan R, Gatley SJ, Makriyannis A. Preparation of iodine-123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor Journal of Labelled Compounds and Radiopharmaceuticals. 38: 875-881. DOI: 10.1002/(Sici)1099-1344(199610)38:10<875::Aid-Jlcr908>3.0.Co;2-G  0.382
1995 Xie XQ, Eissenstat M, Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sciences. 56: 1963-70. PMID 7776820 DOI: 10.1016/0024-3205(95)00177-8  0.369
1995 Morse KL, Fournier DJ, Li X, Grzybowska J, Makriyannis A. A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sciences. 56: 1957-62. PMID 7776819 DOI: 10.1016/0024-3205(95)00176-7  0.424
1995 Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sciences. 56: 1949-55. PMID 7776818 DOI: 10.1016/0024-3205(95)00175-6  0.405
1995 Pertwee RG, Fernando SR, Griffin G, Abadji V, Makriyannis A. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations European Journal of Pharmacology. 272: 73-78. PMID 7713152 DOI: 10.1016/0014-2999(94)00618-H  0.348
1995 Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochimica Et Biophysica Acta. 1259: 173-9. PMID 7488638 DOI: 10.1016/0005-2760(95)00157-8  0.404
1994 Yan G, Yin D, Khanolkar AD, Compton DR, Martin BR, Makriyannis A. Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist. Journal of Medicinal Chemistry. 37: 2619-22. PMID 8057304 DOI: 10.1021/Jm00042A015  0.321
1994 Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medicinal Chemistry. 37: 1889-93. PMID 8021930 DOI: 10.1021/Jm00038A020  0.399
1994 Duclos RI, Chia HH, Abdelmageed OH, Esber H, Fournier DJ, Makriyannis A. Syntheses of racemic and nearly optically pure ether lipids and evaluation of in vitro antineoplastic activities. Journal of Medicinal Chemistry. 37: 4147-54. PMID 7990114 DOI: 10.1021/Jm00050A011  0.308
1994 Guo Y, Abadji V, Morse KL, Fournier DJ, Li X, Makriyannis A. (-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. Journal of Medicinal Chemistry. 37: 3867-70. PMID 7966145 DOI: 10.1021/Jm00049A002  0.382
1994 Tius MA, Makriyannis A, Long Zoua X, Abadji V. Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity Tetrahedron. 50: 2671-2680. DOI: 10.1016/S0040-4020(01)86983-0  0.362
1993 DiMeglio CM, Froimowitz M, Makriyannis A. Conformational analysis of the opioid phenylmorphan and its 9 alpha-methyl analogue in solution using high-resolution nuclear magnetic resonance spectroscopy. Pharmaceutical Research. 10: 1200-1205. PMID 8415408 DOI: 10.1023/A:1018928604461  0.308
1993 Martin BR, Compton DR, Semus SF, Lin S, Marciniak G, Grzybowska J, Charalambous A, Makriyannis A. Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC. Pharmacology, Biochemistry, and Behavior. 46: 295-301. PMID 8265683 DOI: 10.1016/0091-3057(93)90356-X  0.35
1992 Froimowitz M, DiMeglio CM, Makriyannis A. Conformational preferences of the kappa-selective opioid agonist U50488. A combined molecular mechanics and nuclear magnetic resonance study. Journal of Medicinal Chemistry. 35: 3085-3094. PMID 1324314 DOI: 10.1021/Jm00095A001  0.311
1992 Charalambous A, Yan G, Houston DB, Howlett AC, Compton DR, Martin BR, Makriyannis A. 5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. Journal of Medicinal Chemistry. 35: 3076-9. PMID 1323683 DOI: 10.1021/Jm00094A023  0.38
1992 Yang D, Mavromoustakos T, Beshah K, Makriyannis A. Amphipathic interactions of cannabinoids with membranes. A comparison between Δ8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR Biochimica Et Biophysica Acta. 1103: 25-36. PMID 1309660 DOI: 10.1016/0005-2736(92)90053-O  0.302
1991 Makriyannis A, DiMeglio CM, Fesik SW. Anesthetic steroid mobility in model membrane preparations as examined by high-resolution 1H and 2H NMR spectroscopy. Journal of Medicinal Chemistry. 34: 1700-3. PMID 2033593 DOI: 10.1021/Jm00109A024  0.519
1991 Burstein SH, Audette CA, Charalambous A, Doyle SA, Guo Y, Hunter SA, Makriyannis A. Detection of cannabinoid receptors by photoaffinity labelling. Biochemical and Biophysical Research Communications. 176: 492-7. PMID 1850270 DOI: 10.1016/0006-291X(91)90951-3  0.353
1991 Yang D, Banijamali A, Charalambous A, Marciniak G, Makriyannis A. Solid state 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes. Pharmacology, Biochemistry and Behavior. 40: 553-557. PMID 1806945 DOI: 10.1016/0091-3057(91)90362-6  0.304
1991 Charalambous A, Lin S, Marciniak G, Banijamali A, Friend FL, Compton DR, Martin BR, Makriyannis A. Pharmacological evaluation of halogenated delta 8-THC analogs. Pharmacology, Biochemistry, and Behavior. 40: 509-12. PMID 1666915 DOI: 10.1016/0091-3057(91)90355-6  0.341
1990 Makriyannis A, Rapaka RS. The molecular basis of cannabinoid activity. Life Sciences. 47: 2173-84. PMID 2266785 DOI: 10.1016/0024-3205(90)90147-J  0.372
1988 Schyf CJVd, Mavromoustakos T, Makriyannis A. The conformation of (-) 8 α and (-) 8 β-hydroxy-δ9-tetrahydrocannabinols and their interactions with model membranes Life Sciences. 42: 2231-2239. PMID 2836679 DOI: 10.1016/0024-3205(88)90375-X  0.301
1983 Makriyannis A, Fesik S. Mechanism of steroid anesthetic action: interactions of alphaxalone and delta 16-alphaxalone with bilayer vesicles. Journal of Medicinal Chemistry. 26: 463-5. PMID 6834378 DOI: 10.1021/Jm00358A001  0.483
1983 MAKRIYANNIS A, FESIK S. ChemInform Abstract: MECHANISM OF STEROID ANESTHETIC ACTION: INTERACTIONS OF ALPHAXALONE AND Δ16-ALPHAXALONE WITH BILAYER VESICLES Chemischer Informationsdienst. 14. DOI: 10.1002/chin.198334355  0.42
1983 DE JONG AP, FESIK SW, MAKRIYANNIS A. ChemInform Abstract: CONFORMATIONAL REQUIREMENTS FOR NOREPINEPHRINE UPTAKE INHIBITION BY PHENETHYLAMINES IN BRAIN SYNAPTOSOMES. EFFECTS OF α-ALKYL SUBSTITUTION Chemischer Informationsdienst. 14. DOI: 10.1002/chin.198322358  0.454
1982 de Jong AP, Fesik SW, Makriyannis A. Conformational requirements for norepinephrine uptake inhibition by phenethylamines in brain synaptosomes. Effects of alpha-alkyl substitution. Journal of Medicinal Chemistry. 25: 1438-41. PMID 7154004 DOI: 10.1002/Chin.198322358  0.504
1982 Makriyannis A, Bowerman D, Sze PY, Fournier D, de Jong AP. Structure activity correlations in the inhibition of brain synaptosomal 3H-norepinephrine uptake by phenethylamine analogs. The role of alpha-alkyl side chain and methoxyl ring substitutions. European Journal of Pharmacology. 81: 337-40. PMID 7117379 DOI: 10.1016/0014-2999(82)90454-X  0.32
1982 Makriyannis A, Fesik S. Methoxy group conformations of phenyl methyl ethers in solution Journal of the American Chemical Society. 104: 6462-6463. DOI: 10.1021/Ja00387A058  0.48
1981 Henkel JG, Sikand N, Makriyannis A, Gianutsos G. Synthesis and adrenoceptor affinity of some highly polar β-substituted catecholamines Journal of Medicinal Chemistry. 24: 1258-1260. PMID 7328588 DOI: 10.1002/Chin.198211177  0.347
1981 Knittel JJ, Makriyannis A. Studies on phenethylamine hallucinogens. 2. Conformations of arylmethoxyl groups using 13C NMR. Journal of Medicinal Chemistry. 24: 906-9. PMID 7277405 DOI: 10.1021/Jm00139A031  0.314
1980 Makriyannis A, Fesik SW. Effects of anesthetics on sulfate transport in the red cell. Journal of Neuroscience Research. 5: 25-33. PMID 7381978 DOI: 10.1002/Jnr.490050105  0.483
1980 Weintraub HJ, Nichols DE, Makriyannis A, Fesik SW. Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. Journal of Medicinal Chemistry. 23: 339-41. PMID 7365752 DOI: 10.1002/Chin.198034159  0.497
1980 Makriyannis A, Fesik S. Specific perturbations in erythrocyte membranes and lipid bilayers by anesthetic steroids Drug and Alcohol Dependence. 6: 77. DOI: 10.1016/0376-8716(80)90406-8  0.478
1980 WEINTRAUB HJR, NICHOLS DE, MAKRIYANNIS A, FESIK SW. ChemInform Abstract: CONFORMATIONAL ENERGY DIFFERENCES BETWEEN SIDE CHAIN ALKYLATED ANALOGS OF THE HALLUCINOGEN 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE Chemischer Informationsdienst. 11. DOI: 10.1002/chin.198034159  0.42
1973 Smissman EE, Makriyannis A. Azodicarboxylic acid esters as dealkylating agents. The Journal of Organic Chemistry. 38: 1652-7. PMID 4709670 DOI: 10.1021/Jo00949A007  0.527
1973 SMISSMAN EE, MAKRIYANNIS A. ChemInform Abstract: AZODICARBONSAEUREDIESTER ALS DESALKYLIERUNGSMITTEL Chemischer Informationsdienst. 4: no-no. DOI: 10.1002/chin.197333202  0.442
1971 Smissman E, Makriyannis A, Walaszek E. Additions and Corrections - Synthesis and Pharmacology of N-Cyano-(β-arylethyl)amines. Journal of Medicinal Chemistry. 14: 1251-1251. DOI: 10.1021/Jm00294A604  0.488
1970 Smissman EE, Makriyannis AC, Walaszek EJ. Synthesis and pharmacology of N-cyano-(beta-arylethyl)amines. Journal of Medicinal Chemistry. 13: 640-4. PMID 5466125 DOI: 10.1021/Jm00298A014  0.484
1970 Smissman EE, Makriyannis AC. Solvent effects in the NMR spectra of cyano compounds. Journal of Pharmaceutical Sciences. 59: 1186-7. PMID 5457343 DOI: 10.1002/jps.2600590832  0.488
1970 SMISSMAN EE, MAKRIYANNIS AC, WALASZEK EJ. ChemInform Abstract: SYNTH. UND PHARMAKOLOGIE VON N-CYAN-(BETA-ARYLAETHYL)-AMINEN Chemischer Informationsdienst. Organische Chemie. 1: no-no. DOI: 10.1002/chin.197041277  0.465
Show low-probability matches.